International Journal of Hematology

, Volume 89, Issue 1, pp 34–38

Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience

Authors

  • Shuqing Lü
    • Department of Hematology, Changhai HospitalSecond Military Medical University
  • Jianmin Wang
    • Department of Hematology, Changhai HospitalSecond Military Medical University
  • Xiaoqian Xu
    • Department of Hematology, Changhai HospitalSecond Military Medical University
  • Xiong Ni
    • Department of Hematology, Changhai HospitalSecond Military Medical University
  • Chongmei Huang
    • Department of Hematology, Changhai HospitalSecond Military Medical University
  • Huiying Qiu
    • Department of Hematology, Changhai HospitalSecond Military Medical University
  • Xiaoxia Hu
    • Department of Hematology, Changhai HospitalSecond Military Medical University
    • Department of Hematology, Changhai HospitalSecond Military Medical University
Original Article

DOI: 10.1007/s12185-008-0218-9

Cite this article as:
Lü, S., Wang, J., Xu, X. et al. Int J Hematol (2009) 89: 34. doi:10.1007/s12185-008-0218-9

Abstract

The aim of the present study was to evaluate the effectiveness of bortezomib combined with epirubicin, dexamethasone, and thalidomide (BADT) for the treatment of multiple myeloma (MM). The BADT regimen consisted of a maximum of eight 4-week cycles of: intravenous bortezomib (1.0 mg/m2) and intravenous epirubicin (12 mg/m2) on days 1, 4, 8, and 11; dexamethasone (20 mg) on days 1, 2, 4, 5, 8, 9, 11, and 12; and oral thalidomide (100 mg/m2) on days 1–28. Twelve patients with MM were included in the study, of whom four had not been previously treated and eight had been previously treated with at least one cycle of a systemic combined regimen. All the patients completed at least two cycles of treatment, with an average of five cycles; the complete response (CR) rate was 83.3% (10/12) and stabilization of disease was 16.7% (2/12). The average number of cycles required to achieve CR was 1.9 (range 1–6). In three patients, mobilization of peripheral blood stem cells allowed a sufficient quantity of CD34+ cells to be harvested for future autotransplantation. The main adverse reactions included peripheral neuropathy (4/12), thrombocytopenia (3/12), electrocardiographic abnormalities (4/12), neutropenia (5/12), and liver function impairment (4/12), primarily grade I–II. Infection occurred in four patients with neutropenia, including one patient who developed sepsis. The estimated 1-year overall survival rate was 91.7 ± 8.0%, and the estimated 1-year disease-free survival was 75.0 ± 12.5%. BADT is a highly effective combined regimen, with acceptable toxicity, for the treatment of multiple myeloma.

Keywords

Multiple myelomaBortezomibEpirubicinDexamethasoneThalidomide

Copyright information

© The Japanese Society of Hematology 2008